Abacavir
- Generic Name
- Abacavir
- Brand Names
- Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
- Drug Type
- Small Molecule
- Chemical Formula
- C14H18N6O
- CAS Number
- 136470-78-5
- Unique Ingredient Identifier
- WR2TIP26VS
- Background
Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
- Indication
Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
HIV Drugs Show Promising Potential to Reduce Alzheimer's Risk by Up to 13% Annually
• UVA Health researchers discovered that HIV medications called NRTIs significantly reduce Alzheimer's risk, with annual decreases of 6-13% observed across two major health insurance databases.
• The protective effect appears specific to NRTIs, which block inflammasomes linked to Alzheimer's development, and could potentially prevent approximately 1 million new cases worldwide each year.
• Researchers are now calling for clinical trials of both existing NRTIs and a newly developed inflammasome-blocking drug called K9, which they describe as a safer and more effective alternative.
Lupin Gains FDA Approvals for HIV, Cystic Fibrosis, and Heart Failure Generics
• Lupin receives FDA approval for generic Sacubitril/Valsartan tablets, a heart failure therapy, targeting a $6.06 billion market.
• Tentative FDA approval granted to Lupin for generic Abacavir/Dolutegravir/Lamivudine tablets, an HIV treatment for pediatric patients.
• Lupin's Ivacaftor oral granules, a generic for cystic fibrosis, also receive tentative FDA approval with potential for 180-day exclusivity.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath